Genomic Valley Biotech share news and announcements
BSE: 539206Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹35.92.
- Under BSE's graded surveillance, stage 0, on the list for 22 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 30 Oct 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹12 Cr4,774th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 15 Aug 2026
- 567.4
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 15 Aug 2026
- 0.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 15 Aug 2026
- 0.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day.
- 2,994
Genomic Valley Biotech share news and announcements
489 announcements, routine notices left out, newest first. Page 5 of 10.
Dec 2021
Nov 2021
24 Nov · Board meeting
Meeting on 24 Nov 2021: annual general meeting1 Nov · Board meeting
Meeting on 12 Nov 2021: quarterly results
Oct 2021
21 Oct · Shareholding for the Period Ended September 30, 2021
Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click ....14 Oct · Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2021
Aug 2021
2 Aug · Board meeting
Meeting on 10 Aug 2021: quarterly results
Jul 2021
28 Jul · Disclosure Of Related Party Transactions Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended 31.03.2021
9 Jul · Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 07 Jul · Shareholding for the Period Ended June 30, 2021
Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click ....
Jun 2021
29 Jun · Outcomes Of Board Meeting
23 Jun · Board meeting
Meeting on 29 Jun 2021: quarterly results and audited results22 Jun · Board meeting
Meeting on 22 Jun 202122 Jun · Outcomes Of The Board Meeting
Apr 2021
28 Apr · Certificate Pursuant To Regulation 40 (10) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
21 Apr · Shareholding for the Period Ended March 31, 2021
Shareholding Pattern for the Period Ended March 31, 2021. For more details, kindly Click ....16 Apr · Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 016 Apr · Submission Of Compliance Certificate Pursuant To Regulation 7 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
12 Apr · Intimation Regarding The Applicability Of SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144
Feb 2021
2 Feb · Board meeting
Meeting on 11 Feb 2021: quarterly results
Jan 2021
12 Jan · Statement Of Investor Complaints For The Quarter Ended December 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 08 Jan · Shareholding for the Period Ended December 31, 2020
Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click ....1 Jan · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Dec 2020
8 Dec · Reg. 34 (1) Annual Report